Stoke Therapeutics Inc (NASDAQ: STOK) on Tuesday, soared 12.25% from the previous trading day, before settling in for the closing price of $22.37. Within the past 52 weeks, STOK’s price has moved between $5.35 and $38.69.
A company in the Healthcare sector has jumped its sales by 1.74% annually for the last half of the decade. The company achieved an average annual earnings per share of 111.02%. With a float of $49.09 million, this company’s outstanding shares have now reached $55.12 million.
Stoke Therapeutics Inc (STOK) Insider and Institutional Ownership
Observing investor behavior towards Biotechnology industry stocks is more important than anything else. The insider ownership of Stoke Therapeutics Inc is 14.05%, while institutional ownership is 109.66%. The most recent insider transaction that took place on Nov 03 ’25, was worth 152,566. In this transaction CHIEF MEDICAL OFFICER of this company sold 5,931 shares at a rate of $25.72, taking the stock ownership to the 7,195 shares. Before that another transaction happened on Nov 03 ’25, when Company’s Officer proposed sale 5,931 for $30.04, making the entire transaction worth $178,167.
Stoke Therapeutics Inc (STOK) Latest Financial update
As on 12/31/2024, Multinational firm has announced its last quarter scores, in which it reported -0.18 earnings per share (EPS) for the period topping the consensus outlook (set at -0.53) by 0.35. Wall Street market experts anticipate that the next fiscal year will bring earnings of -0.69 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around 111.02% per share during the next fiscal year. For the long-term projections, market analysts anticipate that the company’s EPS will plunge by -14.98% during the next five years compared to 1.74% growth over the previous five years of trading.
Stoke Therapeutics Inc (NASDAQ: STOK) Trading Performance Indicators
Stoke Therapeutics Inc (STOK) is currently performing well based on its current performance indicators. A quick ratio of 6.53 was reported for the most recent quarter. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 6.97. Likewise, its price to free cash flow for the trailing twelve months is 27.39.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is 0.66, a number that is poised to hit -0.70 in the next quarter and is forecasted to reach -2.99 in one year’s time.
Technical Analysis of Stoke Therapeutics Inc (STOK)
Let’s dig in a bit further. During the last 5-days, its volume was 1.28 million. That was better than the volume of 0.91 million it reported in year-ago period. As of the previous 9 days, the stock’s Stochastic %D was 25.23%.
During the past 100 days, Stoke Therapeutics Inc’s (STOK) raw stochastic average was set at 50.65%, which indicates a significant increase from 35.32% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 2.09 in the past 14 days, which was higher than the 1.38 volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $26.63, while its 200-day Moving Average is $14.82. However, in the short run, Stoke Therapeutics Inc’s stock first resistance to watch stands at $26.24. Second resistance stands at $27.38. The third major resistance level sits at $29.59. If the price goes on to break the first support level at $22.89, it is likely to go to the next support level at $20.68. The third support level lies at $19.54 if the price breaches the second support level.
Stoke Therapeutics Inc (NASDAQ: STOK) Key Stats
Market capitalization of the company is 1.43 billion based on 57,117K outstanding shares. Right now, sales total 36,560 K and income totals -88,980 K. The company made 10,630 K in profit during its latest quarter, and -38,350 K in sales during its previous quarter.
